|
|
|
|
|
| First Name: | Eef | | Last Name: | Hogervorst | | Title: | Professor | | Advanced Degrees: | PhD | | Affiliation: | Loughborough University | | Department: | School of SSEHS | | Street Address 1: | Brockington building | | Street Address 2: | Ashby road | | City: | Loughborough | | State/Province: | Leicestershire | | Zip/Postal Code: | LE11 2SZ | Country/Territory: | United Kingdom | | Phone: | +44 1509 223020 | | Fax: | +44 1509 223940 | | Email Address: |  |
Disclosure:
(view policy)
|
Member reports the following financial or other potential conflicts of interest: [Last Modified: 3 February 2006]
In the past I have done consultancy work for Wyett pharmacueticals (expert panel to discuss WHIMS results, 2003), Solvay pharmaceuticals (reviews of literature, 2004/2005), Cognitive Drug Research (report reviews, 2002), Organon (literature reviews 1997) and did collaborative work with Voyager pharmaceuticals (LH assays paid by R Bowen 2002)
|
|
|
View all comments by Eef Hogervorst
|
Alzheimer Disease, Stroke and Trauma, Aging Process
|
Neuroimmunology, Electrophysiology, Drug screening, Apoptosis/Cell cycle, Neurobiology, Neurotransmission, Brain imaging, Chemistry/Pharmacology, Clinical trials, Diagnosis, Genetics, Oxidative Stress, Bioinformatics/Statistics, Epidemiology
|
Professor Hogervorst currently holds the position of Chair of Biological Psychology at the University of Loughborough and is an internationally recognized expert in hormones and Alzheimer's disease. Professor Hogervorst is often invited as a key-note speaker at international conferences, reviews papers and grant proposals in her field and has acted as a consultant for the pharmaceutical industry and as a scientific advisor for the British Andropause Society. She is an elected member of the Medical Research Council college of experts (Neuroscience and Mental health), a young fellow of the Royal Society of Medicine in London and section Head of F1000 Women and reproductive health. Professor Hogervorst did her PhD at the University of Maastricht, winning several awards for her work on hormones and cognitive function. Since 1998, she has worked in the U.K., starting at the University of Oxford and then at the University of Cambridge before moving to Loughborough in 2005. As Associate Professor she was involved in the Rural Aging and Memory Study in Arkansas, USA. Professor Hogervorst studies early diagnoses and modifiable risk and protective factors (such as hormones and nutrition) for dementia and age-related cognitive decline in collaboration with researchers in the USA, UK, Holland, Germany and Indonesia. Her specialized cognitive test battery is running in KEEPS and several other hormone related studies in Europe and the USA. She collaborates with several large cohort studies (Health ABC, WHIMS, MRC CFAS, OPTIMA) to look at modifiable factors for AD |
1. Hogervorst, E. Bandelow, S & Moffat, S.D. Increasing testosterone levels and effects on cognitive functions in elderly men and women: a review.Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):531-40.
2. Hogervorst, E., Bandelow, S., Combrinck, M, Smith, A.D. (2004c). Low free testosterone is an independent risk factor in AD. Exp Gerontol. Nov-Dec;39(11-12):1633-9.
3. Hogervorst, E., deJager, C., Budge, M., & Smith, A.D. (2004a). Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women Psychoneuroendocrinology Volume 29, Issue 3, April 2004, Pages 405-421
4. Hogervorst, E. Bandelow, S., Combrinck, M. Irani, S.. & Smith, A.D. (2003b). The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in post-mortem confirmed cases: added value of a decision- tree approach. Dementia;16(3):170-180
5. Hogervorst, E., Williams, J., Combrinck, M., Smith, A.D. (2003a). High levels of serum estradiol in women with Alzheimer's disease: the importance of the sensitivity of the assay method. Eur J Clin Endo, Jan 148, 67-72
6. Hogervorst, E., Lehmann, D.J., Warden, D.R., McBroom, J., Smith, A.D. (2002f). Apolipoprotein E ε4 and testosterone interact in the risk of Alzheimer’s disease in men. Int J Geriatr Psychiatry, 17, 938-940
7. Hogervorst, E., Yaffe, K., Richards, M., Huppert, F.A. (2002e) Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane-Database-Syst-Rev. 2002; (3): CD003799.
8. Hogervorst, E., Yaffe, K., Richards, M., Huppert, F.A. (2002d) Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane-Database-Syst-Rev. 2002:CD003122.
9.Hogervorst, E. & Smith, A.D. (2002c). The interaction of serum folate and estradiol levels in Alzheimer's disease. Neuroendocrinology Letters, April 23(2) 67-72.
10. Hogervorst, E., Mendes Ribeiro, H., Molyneux, A., Budge, M., Smith A.D. (2002b). Serum homocysteine, cerebrovascular risk factors and white matter low attenuation on CT scans in patients with post-mortem confirmed AD. Arch Neurology, May 59: 787-793.
11.Hogervorst, Eva, Marc Combrinck Pablo Lapuerta, Judith Rue Kate Swales Marc Budge (2002a). The Hopkins Verbal Learning Test and screening for dementia. Dement Geriatr Cogn Disord; Dec 2001 13:13-20.
12.Hogervorst, E., Williams, J.W., Budge, M., Barnetson, L., Smith, A.D. (2001). Serum total testosterone is lower in men with Alzheimer’s disease. Neuroendocrinology Letters, 22, 163-168.
Hogervorst, E., Williams, J.W., Budge, M., Riedel, W.J., Jolles, J. (2000c). The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analyses. Neuroscience, 101 (3), 485-512.
Hogervorst, E., Riedel, W., Boshuisen, M.L., & Jolles, J. (1999b) The effects of HRT on cognitive functions in elderly women. Psychoneuroendocrinology, 24(1):43-68
|
- That we do not know why estrogens do not protect against dementia and whether there are alternative hormone treatments that may do this
- To find early markers of dementia
|
Large international treatment trials involving brain scanning techniques lasting over 20 years |
We found that testosterone probably has a dose and age dependent effect in improving memory functions in men (see Hogervorst et al 2005 for a review) which may be further modified by genetic profiles (APOE genotype) |
Large well controlled long term (2 years at least) treatment trials |
That sex steroids are only effective in middle-aged hypogonadal men and women |
|
|
|
|
|
|
Home
